Please wait
Calculation of Filing Fee Table
Form S-3
(Form Type)
Xeris Biopharma Holdings, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered (1) | Proposed Maximum Offering Price Per Unit (2) | Maximum Aggregate Offering Price (3) | Fee Rate | Amount of Registration Fee (3) | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial Effective Date | Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward |
| Newly Registered Securities |
| Primary Offering of Securities: | | | | | | | | | |
| Fees to Be Paid | Equity | Common
Stock,
par value
$0.0001 per
share
| 457(o) | — | — | — | — | — | | | | |
| Fees to Be Paid | Equity | Preferred
Stock, par
value
$0.0001 per
share
| 457(o) | — | — | — | — | — | | | | |
| Fees to Be Paid | Debt | Debt Securities | 457(o) | — | — | — | — | — | | | | |
| Fees to Be Paid | Equity | Warrants | 457(o) | — | — | — | — | — | | | | |
| Fees to Be Paid | Equity | Units | 457(o) | — | — | — | — | — | | | | |
| Fees to Be Paid | Unallocated (Universal) Shelf | (1) | 457(o) | $250,000,000 | — | $250,000,000 | $0.00015310 | $38,275 | | | | |
| Total Offering Amounts | | $250,000,000 | | $38,275 | | | | |
| Total Fees Previously Paid | | | | — | | | | |
| Total Fee Offsets | | | | $23,175 (4) | | | | |
| Net Fee Due | | | | $15,100 | | | | |
Table 2: Fee Offset Claims and Sources
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Rule 457(p) |
| Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid with Fee Offset Source |
| Fee Offset Claims | Xeris Biopharma Holdings, Inc. | S-3 | 333-262404 | January 28, 2022 | | $23,175 (4) | Unallocated (Universal Shelf) | Unallocated (Universal Shelf) | (4) | $250,000,000 | |
| Fee Offset Sources | Xeris Biopharma Holdings, Inc. | S-3 | 333-262404 | | January 28, 2022 | | | | | | $23,175 (4) |
(1) The amount to be registered consists of up to $250,000,000 of an indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units consisting of two or more of these securities in any combination as may be sold from time to time by the registrant. There is also being registered hereunder such currently indeterminate number of shares of common stock, preferred stock, debt securities, warrants or other securities of the registrant in any combination as may be issued upon the conversion, exchange or exercise of any securities that provide for such issuance. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities.
(2) The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.
(3) The proposed maximum aggregate offering price has been estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act. The aggregate public offering price of the securities registered hereunder will not exceed $250,000,000.
(4) The registrant has previously registered the offer and sale of up to $250,000,000 of securities pursuant to the Registration Statement on Form S-3 (File No. 333-262404), as filed by the Company with the Securities and Exchange Commission on January 28, 2022 (the “Prior Registration Statement”). In connection with the filing of the Prior Registration Statement, the registrant made a contemporaneous fee payment in the amount of $23,175. Of the $250,000,000 of securities registered for potential issuance and sale by the Registrant under the Prior Registration Statement, all of the securities remain unsold (the “Unsold Securities”). Pursuant to Rule 457(p) under the Securities Act, the registration fee of $23,175 that has already been paid and remains unused with respect to the Unsold Securities will offset any registration fee due in connection with this registration statement. Concurrently with the filing of this registration statement, any offering of the Unsold Securities pursuant to the Prior Registration Statement is hereby terminated.